All In Biotech

Drug Trial Radar · NCT02813265

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease

Last checked: Nov 19, 2026Latest source record: Feb 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 918 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

918

Actual

Start

Jun 2016

Primary completion

Oct 2017

Study completion Oct 2017

Sponsor

Lead sponsor
Kala Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).

Conditions

  • Dry Eye Syndromes
  • Keratoconjunctivitis Sicca

Interventions

  • KPI-121 0.25% Ophthalmic SuspensionDrug

  • Vehicle of KPI-121 0.25% Ophthalmic SuspensionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15)Time frame: Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
  2. Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)Time frame: Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
  3. Change From Baseline/Visit 2 (Day 1) in Corneal Fluorescein Staining Score at Visit 4 (Day 15)Time frame: Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
  4. Change From Baseline/Visit 2 (Day 1) Ocular Discomfort Severity at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular DiscomfortTime frame: Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)

Locations

60 sites in 1 country. Site status is shown where the registry gives one.

  • Cornea and Cataract Consultants of Arizona

    Phoenix, Arizona

  • Schwartz Laser Eye Center

    Scottsdale, Arizona

  • Eyecare Arkansas, P.A.

    Little Rock, Arkansas

  • Little Rock Eye Clinic, LLP

    Little Rock, Arkansas

  • Sall Research Medical Center

    Artesia, California

  • Orange County Ophthalmology Medical Group

    Garden Grove, California

  • United Medical Research Institute

    Inglewood, California

  • North Valley Eye Medical Group

    Mission Hills, California

  • Montebello Medical Center, Inc.

    Montebello, California

  • LoBue Laser and Eye Medical Center

    Murrieta, California

  • Eye Research Foundation

    Newport Beach, California

  • Pendleton Eye Center

    Oceanside, California

  • North Bay Eye Associates, Inc.

    Petaluma, California

  • Martel Eye Medical Group

    Rancho Cordova, California

  • Sacramento Eye Consultants

    Sacramento, California

  • Eye Center of Northern Colorado, PC

    Fort Collins, Colorado

  • Corneal Consultants of Colorado

    Littleton, Colorado

  • The Eye Center of Southern CT, P.C.

    Hamden, Connecticut

  • Florida Eye Microsurgical Institute, Inc.

    Boynton Beach, Florida

  • Eye Associates of Fort Myers

    Fort Myers, Florida

  • Shettle Eye Research, Inc.

    Largo, Florida

  • Atlantic Eye Center

    Palm Coast, Florida

  • The Eye Center of North Florida

    Panama City, Florida

  • Dixon Eye Care

    Albany, Georgia

  • Jacksoneye, S. C.

    Lake Villa, Illinois

  • Midwest Cornea Associates, LLC

    Indianapolis, Indiana

  • Stiles EyeCare Excellence and Glaucoma Institute

    Overland Park, Kansas

  • Clinical Eye Research of Boston

    Winchester, Massachusetts

  • Chu Vision Institute

    Bloomington, Minnesota

  • Lifelong Vision Foundation at Pepose Vision Institute

    Chesterfield, Missouri

  • Ophthalmology Associates

    St Louis, Missouri

  • Ophthalmology Consultants, Ltd.

    St Louis, Missouri

  • Wellish Vision Institute

    Las Vegas, Nevada

  • Matossian Eye Associates

    Pennington, New Jersey

  • Rochester Ophthalmological Group, PC

    Rochester, New York

  • Cornea Consultants of Albany

    Slingerlands, New York

  • South Shore Eye Center, LLP

    Wantagh, New York

  • Mundorf Eye Center

    Charlotte, North Carolina

  • Firozvi Research, LLC / North Carolina Eye, Ear, Nose & Throat

    Durham, North Carolina

  • Eyecare Center

    Raleigh, North Carolina

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.